Translational oncology

This section aims to consider publications which bridge laboratory basic science and applied clinical research. The section will publish studies of diagnostic and prognostic markers which may ultimately be applicable in a clinical setting with a special focus on molecular and experimental pathology. Submissions need to be REMARK compliant as established in NCI-EORTC's "Reporting Recommendations for Tumor Marker Prognostic Studies " (J Clin Oncol 23:9067, 2005) and should report biomarkers that have a clear biologic relevance to a particular tumor type.

Previous Page Page 1 of 35 Next Page
  1. Study protocol

    Imatinib treatment of poor prognosis mesenchymal-type primary colon cancer: a proof-of-concept study in the preoperative window period (ImPACCT)

    The identification of four Consensus Molecular Subtypes (CMS1–4) of colorectal cancer forms a new paradigm for the design and evaluation of subtype-directed therapeutic strategies. The most aggressive subtype ...

    I. Ubink, H. J. Bloemendal, S. G. Elias, M. A. Brink, M. P. Schwartz, Y. C. W. Holierhoek, P. M. Verheijen, A. W. Boerman, R. H. J. Mathijssen, W. W. J. de Leng, R. A. de Weger, W. M. U. van Grevenstein, M. Koopman, M. P. Lolkema, O. Kranenburg and I. H. M. Borel Rinkes

    BMC Cancer 2017 17:282

    Published on: 19 April 2017

  2. Research article

    Prognostic significance of TRAIL-R3 and CCR-2 expression in tumor epithelial cells of patients with early breast cancer

    Tumor epithelial cells (TEpCs) and spindle-shaped stromal cells, not associated with the vasculature, of patients with early breast cancer express osteoprotegerin (OPG), tumor necrosis factor-related apoptosis...

    Vivian Labovsky, Leandro Marcelo Martinez, Kevin Mauro Davies, María de Luján Calcagno, Hernán García-Rivello, Alejandra Wernicke, Leonardo Feldman, Ayelén Matas, María Belén Giorello, Francisco Raúl Borzone, Hosoon Choi, Scott C. Howard and Norma Alejandra Chasseing

    BMC Cancer 2017 17:280

    Published on: 18 April 2017

  3. Research article

    Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer

    Epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSC) contribute to tumour progression and metastasis. Assessment of transcription factors involved in these two mechanisms can help to identify...

    Tristan Lerbs, Savita Bisht, Sebastian Schölch, Mathieu Pecqueux, Glen Kristiansen, Martin Schneider, Bianca T. Hofmann, Thilo Welsch, Christoph Reissfelder, Nuh N. Rahbari, Johannes Fritzmann, Peter Brossart, Jürgen Weitz, Georg Feldmann and Christoph Kahlert

    BMC Cancer 2017 17:249

    Published on: 7 April 2017

  4. Study protocol

    Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease

    Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies today with an urgent need for novel therapeutic strategies. Biomarker analysis helps to better understand tumor biology and might ...

    Felix C. Popp, Marie Christine Popp, Yue Zhao, Christopher Betzler, Siegfried Kropf, Benjamin Garlipp, Christoph Benckert, Thomas Kalinski, Hans Lippert and Christiane J. Bruns

    BMC Cancer 2017 17:229

    Published on: 29 March 2017

  5. Research article

    Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin

    We evaluated possible diagnostic and prognostic values of serum midkine in malignant pleural mesothelioma in comparison with those of serum mesothelin, a well-established diagnostic biomarker.

    Guntulu Ak, Yuji Tada, Hideaki Shimada, Selma Metintas, Masaaki Ito, Kenzo Hiroshima, Masatoshi Tagawa and Muzaffer Metintas

    BMC Cancer 2017 17:212

    Published on: 23 March 2017

  6. Research article

    Tumor burden monitoring using cell-free tumor DNA could be limited by tumor heterogeneity in advanced breast cancer and should be evaluated together with radiographic imaging

    Accurate measurement of tumor burden in breast cancer disease is essential to improve the clinical management of patients. In this study, we evaluate whether the fluctuations in the fraction of PIK3CA mutant a...

    José Angel García-Saenz, Patricia Ayllón, Marion Laig, Daniel Acosta-Eyzaguirre, Marta García-Esquinas, Myriam Montes, Julián Sanz, Miguel Barquín, Fernando Moreno, Vanesa Garcia-Barberan, Eduardo Díaz-Rubio, Trinidad Caldes and Atocha Romero

    BMC Cancer 2017 17:210

    Published on: 22 March 2017

  7. Research article

    Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways

    Targeted therapies are emerging treatment options for gastric cancer (GC). Patient-derived tumor xenograft(PDX) models of GC closely retain the features of the original clinical cancer, offering a powerful too...

    Haiyong Wang, Jun Lu, Jian Tang, Shitu Chen, Kuifeng He, Xiaoxia Jiang, Weiqin Jiang and Lisong Teng

    BMC Cancer 2017 17:191

    Published on: 14 March 2017

  8. Research article

    The C-reactive protein/albumin ratio, a validated prognostic score, predicts outcome of surgical renal cell carcinoma patients

    The preoperative C-reactive protein/Albumin (CRP/Alb) ratio has been shown to be valuable in predicting the prognosis of patients with certain cancers. The aim of our study is to explore its prognostic value i...

    Shengjie Guo, Xiaobo He, Qian Chen, Guangwei Yang, Kai Yao, Pei Dong, Yunlin Ye, Dong Chen, Zhiling Zhang, Zike Qin, Zhuowei Liu, Yunfei Xue, Meng Zhang, Ruiwu Liu, Fangjian Zhou and Hui Han

    BMC Cancer 2017 17:171

    Published on: 6 March 2017

  9. Research article

    The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation

    Docetaxel based therapy is one of the first line chemotherapeutic agents for the treatment of metastatic castrate-resistant prostate cancer. However, one of the major obstacles in the treatment of these patien...

    D. J. Lundon, A. Boland, M. Prencipe, G. Hurley, A O’Neill, E. Kay, S. T. Aherne, P. Doolan, S. F. Madden, M. Clynes, C. Morrissey, J. M. Fitzpatrick and R. W. Watson

    BMC Cancer 2017 17:163

    Published on: 1 March 2017

  10. Research article

    Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions

    In metastatic breast cancer, the status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), as well as the Ki-67 index sometimes change between prima...

    Hitoshi Inari, Nobuyasu Suganuma, Kae Kawachi, Tatsuya Yoshida, Takashi Yamanaka, Yoshiyasu Nakamura, Mitsuyo Yoshihara, Hirotaka Nakayama, Ayumi Yamanaka, Katsuhiko Masudo, Takashi Oshima, Tomoyuki Yokose, Yasushi Rino, Satoru Shimizu, Yohei Miyagi and Munetaka Masuda

    BMC Cancer 2017 17:160

    Published on: 27 February 2017

  11. Research article

    Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma

    TSPYL5, a putative tumor suppressor gene, belongs to the nucleosome assembly protein family. The chromosomal location of the TSPYL5 gene is 8Q22.1, and its exact role in prostate cancer etiology remains unclear. ...

    Senthil R. Kumar, Jeffrey N. Bryan, Magda Esebua, James Amos-Landgraf and Tanner J. May

    BMC Cancer 2017 17:158

    Published on: 24 February 2017

  12. Research article

    Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer

    Suppressor of cytokine signaling 1 (SOCS1) is considered a tumor suppressor due to frequent epigenetic and micro-RNA-mediated repression of its gene expression in diverse cancers. In prostate cancer (PCa), ele...

    Martin Chevrier, Diwakar Bobbala, Alberto Villalobos-Hernandez, Md Gulam Musawwir Khan, Sheela Ramanathan, Caroline Saucier, Gerardo Ferbeyre, Sameh Geha and Subburaj Ilangumaran

    BMC Cancer 2017 17:157

    Published on: 24 February 2017

  13. Research article

    Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer

    Proliferation may predict response to neoadjuvant therapy of breast cancer and is commonly assessed by manual scoring of slides stained by immunohistochemistry (IHC) for Ki-67 similar to ER and PgR. This metho...

    Hans-Peter Sinn, Andreas Schneeweiss, Marius Keller, Kornelia Schlombs, Mark Laible, Julia Seitz, Sotirios Lakis, Elke Veltrup, Peter Altevogt, Sebastian Eidt, Ralph M. Wirtz and Frederik Marmé

    BMC Cancer 2017 17:124

    Published on: 13 February 2017

  14. Research article

    Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide

    We previously identified three short single peptides (P4, P6 and P7) representing different B-cell epitopes on the extracellular domain of Her-2/neu for a vaccine that was tested in a phase-I clinical trial. H...

    Joshua Tobias, Joanna Jasinska, Karin Baier, Michael Kundi, Nicholas Ede, Christoph Zielinski and Ursula Wiedermann

    BMC Cancer 2017 17:118

    Published on: 9 February 2017

  15. Research article

    Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer

    Body mass index (BMI) is largely investigated as a prognostic and predictive factor in triple-negative breast cancer (TNBC). Overweight and obesity are linked to a variety of pathways regulating tumor-promotin...

    Maddalena Barba, Patrizia Vici, Laura Pizzuti, Luigi Di Lauro, Domenico Sergi, Anna Di Benedetto, Cristiana Ercolani, Francesca Sperati, Irene Terrenato, Claudio Botti, Lucia Mentuccia, Laura Iezzi, Teresa Gamucci, Clara Natoli, Ilio Vitale, Marcella Mottolese…

    BMC Cancer 2017 17:101

    Published on: 6 February 2017

  16. Research article

    BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study

    BK-UM (CRM197) is a mutant form of diphtheria toxin and a specific inhibitor of heparin-binding epidermal growth factor-like growth factor (HB-EGF). We assessed the safety, pharmacokinetics, recommended dose, ...

    Shingo Miyamoto, Fusanori Yotsumoto, Taeko Ueda, Tatsuya Fukami, Ayako Sanui, Kohei Miyata, Sung Ouk Nam, Satoshi Fukagawa, Takahiro Katsuta, Miyako Maehara, Haruhiko Kondo, Daisuke Miyahara, Kyoko Shirota, Toshiyuki Yoshizato, Masahide Kuroki, Hiroaki Nishikawa…

    BMC Cancer 2017 17:89

    Published on: 31 January 2017

Previous Page Page 1 of 35 Next Page

Can't find what you are looking for?

The following sections have not yet been added to this new-look site. In the meantime you can still view them on our old site.